Mike Hennessy Sr

home / authors / mike-hennessy-sr

Articles

ONCOLOGY Remembers Dr Franco Muggia

ONCOLOGY Remembers Dr Franco Muggia

Mike Hennessy Sr
October 14th 2021

ONCOLOGY remembers Dr Franco Muggia's contribution to cancer care.

Questions Linger Around COVID-19’s Origin

Questions Linger Around COVID-19’s Origin

Mike Hennessy Sr
July 10th 2021
Exploring Novel Mechanisms of Action–Then and Now

Exploring Novel Mechanisms of Action–Then and Now

Mike Hennessy Sr
May 16th 2021
Optimizing Therapies For Patients With Lung Cancer

Optimizing Therapies For Patients With Lung Cancer

Mike Hennessy Sr
December 7th 2020
BCMA Offers Hope in Multiple Myeloma

BCMA Offers Hope in Multiple Myeloma

Mike Hennessy Sr
November 13th 2020

B-cell maturation antigen target shows promise for patients with relapsed/refractory multiple myeloma.

Keeping Cancer in "Check"

Keeping Cancer in "Check"

Mike Hennessy Sr
October 13th 2020
Choosing the Right Path

Choosing the Right Path

Mike Hennessy Sr
September 22nd 2020
Finding The Target

Finding The Target

Mike Hennessy Sr
August 12th 2020
Forging Ahead in the COVID-19 era

Forging Ahead in the COVID-19 era

Mike Hennessy Sr
July 15th 2020

The Chairman and founder of MJH Life Sciences discusses the current issue of ONCOLOGY®,

Ensuring Decisional Capacity

Ensuring Decisional Capacity

Mike Hennessy Sr
June 16th 2020
Site Logo

Navigating Uncharted Waters

Mike Hennessy Sr
May 13th 2020

Site Logo

The Rapid Evolution of Breast Cancer Care

Mike Hennessy Sr
April 10th 2020

Site Logo

Improving Outcomes in Multiple Myeloma

Mike Hennessy Sr
March 19th 2020

Site Logo

Advancing Breast Cancer Care

Mike Hennessy Sr
February 25th 2020

Site Logo

Addressing the Highs and Lows in Cancer Treatment

Mike Hennessy Sr
January 16th 2020

While the development of immunotherapy and targeted agents has advanced treatment options for a variety of malignancies, there is still the reminder that not all regimens work in treating cancer.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.
Published: April 21st 2025 | Updated: April 26th 2025
Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma